Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Erbin interacts with NHERF1 and Ezrin to stabilize a membrane ErbB2 signaling complex in HER2-positive breast cancer

Fig. 1

Association of HER2, NHERF1, and Ezrin in hyperplasia and DCIS. A) Immunofluorescence for NHERF1 and Ezrin in day 10 lactating WT mouse mammary glands. All scale bars represent 10µM. B) Immunofluorescence for HER2 with NHERF1 and Ezrin in day 10 lactating MMTV-Neu mouse mammary glands. All scale bars represent 10µM. C) Immunofluorescence for HER2 with NHERF1 (top row) and Ezrin (bottom row) in hyperplastic lesions from MMTV-Neu mammary glands. All scale bars represent 10µM. D) Immunofluorescence for HER2 with Na/K ATPase (top row), NHERF1 (middle row), and Ezrin (bottom row) in human lumen filled DCIS sections. All scale bars represent 10µM. E) Immunofluorescence for HER2 with Na/K ATPase (top row), NHERF1 (middle row), and Ezrin (bottom row) in human sections adjacent to DCIS lesions. All scale bars represent 10µM. F) Gene Set Enrichment Analysis (GSEA) from RNAseq comparing tumor free human breast tissue (normal) vs. human HER2 positive DCIS. G) Enrichment score of apical_junction pathway for HER2 positive DCIS from Hallmark GSEA analysis. H) Correlation of HER2 gene expression with SLC9A3R1 (NHERF1) and EZR (Ezrin) from RNAseq comparing normal breast vs. human HER2 positive DCIS

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us